MTOR and neoplasm: Furthermore, transient inhibition of mTOR between day 30 and day 60 (Fig. 2d) profoundly impacted end-stage tumour formation, compromising the ability of Ctnnb1ex3/WT;R26LSL-MYC hepatocytes to form tumours, resulting in a significant reduction in tumour number and an extension in survival (Fig. 2e).